Lawrence Karsh, MD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Veru Pharmaceuticals
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    NeoGenomic Laboratories
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    EMD Serono
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Minomic
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Nucleix
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Siemans
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Cepheid
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Arivan Research
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Pfizer
    Date added:
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Myovant
    Date added:
    Date updated:
    09/14/2023

Pages

Return to 2022 AUA Annual Meeting Highlights: Prostate Cancer